

Agenda

MOC na ASCO 2023



COLORRETAL

Fábio Kater



MOC na ASCO 2023

- Oncologista Clínico da BP – A Beneficência Portuguesa de São Paulo.
Coordenador da Oncologia da Unidade Hospital BP-Mirante.
- CRM 99.002.

Conflito de interesses



MOC na ASCO 2023

De acordo com a Norma 1595/2000 do Conselho Federal de Medicina e com a RDC 96/2008 da ANVISA, declaro que:

- *Speaker*: AstraZeneca, Jansen, Astellas, Lilly, Bayer, MSD, BMS.
- Estudos: Roche e MSD.
- *Advisory board*: AstraZeneca, Astellas.
- Incentivo de congressos: Daichii, MSD e Roche.

Reto localizado



MOC na ASCO 2023

Plenary session

- **LBA2 - PROSPECT: A randomized phase III trial of neoadjuvant chemoradiation versus neoadjuvant FOLFOX chemotherapy with selective use of chemoradiation, followed by total mesorectal excision (TME) for treatment of locally advanced rectal cancer (LARC) - Alliance N1048.**

Reto localizado



MOC na ASCO 2023

Oral abstract session

- **LBA3503** - Phase III randomized clinical trial comparing the efficacy of neoadjuvant chemotherapy and standard treatment in patients with locally advanced colon cancer: The NeoCol trial. (Dinamarquês)

Oral abstract session

- **LBA3504** - Total neoadjuvant therapy with mFOLFIRINOX versus preoperative chemoradiation in patients with locally advanced rectal cancer: 7-year results of PRODIGE 23 phase III trial, a UNICANCER GI trial.

Reto localizado



MOC na ASCO 2023

Oral abstract session

- **LBA3505** - Long-term outcome of neoadjuvant mFOLFOX6 with or without radiation versus fluorouracil plus radiation for locally advanced rectal cancer: A multicenter, randomized phase III trial. (Chinês)

Poster discussion

- **3519** - Neoadjuvant chemotherapy (NAC) followed by total mesorectal excision (TME) and adjuvant chemotherapy versus TME followed by adjuvant chemotherapy in very low-lying clinical (c) T3 rectal cancer (NAIR): A multicenter, randomized, open-label, phase 2/3 trial.

Reto localizado



MOC na ASCO 2023

Poster discussion

- **3520** - Sustained organ preservation in rectal cancer patients treated with total neoadjuvant therapy: Long-term results of the OPRA trial.

Cólon metastático: Populações especiais



MOC na ASCO 2023

Oral abstract session

- **3505** - Trastuzumab deruxtecan (T-DXd) in patients (pts) with HER2-overexpressing/amplified (HER2+) metastatic colorectal cancer (mCRC): Primary results from the multicenter, randomized, phase 2 DESTINY-CRC02 study.

Poster discussion

- **3513** - Sotorasib (Soto) plus panitumumab (Pmab) and FOLFIRI for previously treated *KRAS* G12C-mutated metastatic colorectal cancer (mCRC): CodeBreakK 101 phase 1b safety and efficacy.

Cólon metastático



MOC na ASCO 2023

Poster discussion

- **3517** - Upfront palliative resection of primary tumor versus no resection in patients with synchronous metastatic colorectal cancer: The randomized phase 3 CAIRO4 study of the Dutch Colorectal Cancer Group (DCCG).

Poster discussion

- **5312** - Overall survival results for trifluridine/tipiracil plus bevacizumab vs capecitabine plus bevacizumab: Results from the phase 3 SOLSTICE study.

Cólon metastático: RASwt



MOC na ASCO 2023

Oral abstract session

- **3507** - Phase III FIRE-4 study (AIO KKK-0114): Influence of baseline liquid biopsy results in first-line treatment efficacy of FOLFIRI/cetuximab in patients with tissue RAS-WT mCRC.

Oral abstract session

- **3508** - Efficacy of panitumumab in patients with left-sided disease, MSS/MSI-L, and *RAS/BRAF* WT: A biomarker study of the phase III PARADIGM trial.

Créditos

MOC na ASCO 2023 © 2023 MOC - Manual de Oncologia Clínica do Brasil. Todos os direitos reservados. São Paulo, SP.
Proibida a reprodução total ou parcial do conteúdo e imagens sem a permissão dos titulares de seus direitos autorais.

Apoio educacional:

